サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1761017

遺伝子検査の世界市場

Genetic Testing

出版日
ページ情報
英文 573 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.41円
遺伝子検査の世界市場
出版日: 2025年07月02日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 573 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

遺伝子検査の世界市場は2030年までに264億米ドルに達する見込み

2024年に150億米ドルと推定される遺伝子検査の世界市場は、2024年から2030年にかけてCAGR 9.9％で成長し、2030年には264億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるがんは、CAGR 9.7%を記録し、分析期間終了時には136億米ドルに達すると予測されます。遺伝性疾患セグメントの成長率は、分析期間中CAGR 10.1%と推定されます。

米国市場は60億米ドルと推定、中国はCAGR 11.9％で成長予測

米国の遺伝子検査市場は2024年に60億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに19億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.3％と10.0％と予測されています。欧州では、ドイツがCAGR 8.4%で成長すると予測されています。

世界の遺伝子検査市場- 主要動向と促進要因まとめ

遺伝子検査とは何か、ヘルスケアにどのような影響を与えるのか？

遺伝子検査は、DNA配列を解析し、遺伝子、染色体、タンパク質の変化を特定することで、遺伝子疾患の存在や発症リスクを示す可能性があります。この種の検査は、がん、心血管疾患、希少な遺伝性疾患など、さまざまな疾患の早期診断と個別化治療計画を可能にし、医療分野に革命をもたらしました。特定の遺伝子変異を特定することで、ヘルスケアプロバイダーは個々の患者に合わせた治療を行うことができ、治療効果を高め、副作用を軽減できる可能性があります。遺伝子検査はまた、出生前スクリーニング、保因者スクリーニング、特定の疾患の発症リスクの予測においても極めて重要な役割を果たしています。

どのような技術の進歩が遺伝子検査を形成しているのでしょうか？

遺伝子検査の分野は、ゲノム技術、特に次世代シーケンサー（NGS）とCRISPRの進歩によって大きな影響を受けています。NGSは、以前必要とされていたコストと時間のほんの一部で、全ゲノムの迅速な配列決定を可能にします。この技術は、遺伝子検査へのアクセス性を拡大しただけでなく、結果の正確性と信頼性も向上させました。一方、遺伝子編集機能で知られるCRISPR技術は、遺伝子の欠陥が病気につながる前に修正する可能性が模索されています。さらに、バイオインフォマティクスの向上と人工知能の統合により、大量の遺伝子データを解析・解釈する能力が強化され、より詳細で実用的な洞察が得られるようになりました。

規制と倫理的配慮は遺伝子検査市場にどのような影響を与えていますか？

遺伝子検査市場は、規制と倫理的配慮の影響を大きく受けています。遺伝子検査が一般的になるにつれて、プライバシー、同意、遺伝情報へのアクセスなどの問題は、世界中の政府に厳しいガイドラインや規制を設けるよう促しています。これらの規制は、遺伝的差別から個人を保護し、遺伝情報の機密性と完全性を確保することを目的としています。さらに、遺伝子検査がどのように使用されるか、例えば出生前スクリーニングや遅発性疾患の発症可能性の判定に使用されるかといった倫理的な懸念は、公共政策を形成し、遺伝子検査サービスに対する消費者の受容と信頼に影響を与え続けています。

遺伝子検査市場の成長の原動力は？

遺伝子検査市場の成長は、遺伝性疾患の有病率の増加、遺伝学における技術の進歩、疾患の早期発見と予防の利点に対する意識の高まりなど、いくつかの要因によってもたらされます。また、消費者直販の遺伝子検査キットの拡大も市場成長に大きく寄与しており、より多くの個人が自分の遺伝的健康を理解するために積極的なステップを踏んでいます。さらに、ヘルスケアシステムは個別化医療をますます採用するようになっており、個別化された治療計画を立てるために遺伝的洞察に大きく依存しています。さらに、政府や民間団体の資金援助による継続的な研究開発活動により、遺伝子検査の新たな用途が次々と発見され、市場のすそ野がさらに広がっています。

セグメント

タイプ（出生前・新生児,診断,予知・予兆,キャリア,ファーマコゲノミクス,その他のタイプ）;アプリケーション（がん,遺伝性疾患,循環器疾患,その他のアプリケーション）

調査対象企業の例（注目の249社）

  • Agilent Technologies, Inc.
  • Asuragen, Inc.
  • Biocartis NV
  • Agena Bioscience, Inc.
  • ARUP Laboratories
  • Bioiberica SAU
  • AutoGenomics, Inc.
  • Biodesix, Inc.
  • Admera Health
  • Annoroad Gene Technology
  • Berry Genomics Co., Ltd.
  • Ariel Precision Medicine, Inc.
  • AlphaBiolabs Ltd.
  • AnchorDx
  • Alexian Brothers of America, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • セグメント分析
  • 市場動向と成長要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP-1392

Global Genetic Testing Market to Reach US$26.4 Billion by 2030

The global market for Genetic Testing estimated at US$15.0 Billion in the year 2024, is expected to reach US$26.4 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Cancer, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$13.6 Billion by the end of the analysis period. Growth in the Genetic Disease segment is estimated at 10.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.0 Billion While China is Forecast to Grow at 11.9% CAGR

The Genetic Testing market in the U.S. is estimated at US$6.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 11.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.3% and 10.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Genetic Testing Market - Key Trends & Drivers Summarized

What Is Genetic Testing and How Does It Impact Healthcare?

Genetic testing involves analyzing DNA sequences to identify changes in genes, chromosomes, or proteins that could indicate the presence of or risk for developing genetic disorders. This type of testing has revolutionized the medical field by enabling early diagnosis and personalized treatment plans for a wide array of diseases, including cancers, cardiovascular diseases, and rare genetic disorders. By identifying specific genetic mutations, healthcare providers can tailor treatments to individual patients, enhancing treatment efficacy and potentially reducing side effects. Genetic testing also plays a pivotal role in prenatal screening, carrier screening, and in predicting an individual’s risk of developing certain diseases.

What Technological Advancements Are Shaping Genetic Testing?

The field of genetic testing has been profoundly impacted by advancements in genomic technologies, particularly next-generation sequencing (NGS) and CRISPR. NGS allows for the rapid sequencing of entire genomes at a fraction of the cost and time previously required. This technology has not only expanded the accessibility of genetic testing but also improved the accuracy and reliability of the results. Meanwhile, CRISPR technology, known for its gene-editing capabilities, is being explored for its potential to correct genetic defects before they can lead to disease. Additionally, improvements in bioinformatics and the integration of artificial intelligence have enhanced the ability to analyze and interpret large sets of genetic data, providing more detailed and actionable insights.

How Are Regulatory and Ethical Considerations Influencing the Genetic Testing Market?

The genetic testing market is heavily influenced by regulatory and ethical considerations. As genetic testing becomes more commonplace, issues such as privacy, consent, and access to genetic information have prompted governments worldwide to establish strict guidelines and regulations. These regulations aim to protect individuals from genetic discrimination and ensure that genetic data is handled with confidentiality and integrity. Furthermore, ethical concerns regarding how genetic testing is used-for example, in prenatal screening or for determining the likelihood of developing late-onset diseases-continue to shape public policy and influence consumer acceptance and trust in genetic testing services.

What Drives the Growth in the Genetic Testing Market?

The growth in the genetic testing market is driven by several factors, including the increasing prevalence of genetic disorders, technological advancements in genetics, and a growing awareness of the benefits of early disease detection and prevention. The expansion of direct-to-consumer genetic testing kits has also significantly contributed to market growth, as more individuals take proactive steps towards understanding their genetic health. Additionally, healthcare systems are increasingly adopting personalized medicine practices, which rely heavily on genetic insights to craft individualized treatment plans. Moreover, ongoing research and development activities, supported by funding from governments and private entities, are continually uncovering new applications for genetic testing, further broadening the market's scope.

SCOPE OF STUDY:

The report analyzes the Genetic Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic, Other Types); Application (Cancer, Genetic Disease, Cardiovascular Disease, Other Applications)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 249 Featured) -

  • Agilent Technologies, Inc.
  • Asuragen, Inc.
  • Biocartis NV
  • Agena Bioscience, Inc.
  • ARUP Laboratories
  • Bioiberica SAU
  • AutoGenomics, Inc.
  • Biodesix, Inc.
  • Admera Health
  • Annoroad Gene Technology
  • Berry Genomics Co., Ltd.
  • Ariel Precision Medicine, Inc.
  • AlphaBiolabs Ltd.
  • AnchorDx
  • Alexian Brothers of America, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Genetic Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • A Prelude to Genetic Testing
    • Top Ten Genetic Diseases Worldwide
    • Different Types of Genetic Tests include
    • Prenatal and Newborn Screening
    • Diagnostic Testing
    • Predictive & Presymptomatic Testing
    • Carrier Identification
    • Pharmacogenomic Testing
    • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
    • Genetic Testing Delivery Models
    • Genetic Sequencing Approaches
    • Expanding Applications to Drive Genetic Testing Market
    • Regional Landscape
    • Prenatal Testing Market to Rise
    • Market Outlook
    • Recent Market Activity
    • Innovations
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • SEGMENT ANALYSIS
    • Prenatal Testing - Changing the World of Pregnancy Care
    • List of Available Prenatal Screening and Diagnostic Tests by Indication
    • Players in the Prenatal and New Born Genetic Testing Market
    • Conventional Invasive Pre-Natal Diagnostic Techniques - A Risky Affair
    • Emergence of Non-Invasive Prenatal Diagnosis (NIPD)
    • Competition Intensifies in the NIPD Market
    • Select Commercially Available NIPD (Genetic) Tests for Aneuploidy in the US
    • Strain on Resources Prevent Wide Adoption of Expanded Carrier Sequencing
    • Predictive Diagnostics
    • Breast Cancer Gene Testing Market to Expand Strongly
    • Myriad Genetics - A Leader in Breast Cancer Testing
    • Discovery of Novel Biomarkers Crucial to Predictive Diagnostics
    • Pharmacogenomics Development Augurs Growth of Genetic Testing Market
  • MARKET TRENDS AND GROWTH DRIVERS
    • Genetic Testing Paves the Way for Personalized Medicine
    • TABLE 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medic
    • Next-Generation Sequencing (NGS) - A Giant Leap in Genome Sequencing
    • Biomarker Discovery Leads to Advanced Genetic Testing
    • Select List of Available Tumor Markers
    • Immense Popularity of Ancestry Testing
    • Increasing Focus on Data Churning
    • Genetic Testing to Explode into Provider Workflow with Intriguing Use Cases
    • Primary Factors Responsible for Waning Interest in Direct-to Consumer Genetic Testing
    • Liquid Biopsy to Facilitate Cancer Diagnosis and Treatment
    • Hybrid Labs to Bridge Gap Between Traditional and DTC Models
    • Rising Prevalence of Cancer and Chromosomal Disorders Augments Demand for Cell-Free DNA Testing
    • Emergence of Rapid DNA Testing
    • Oncology - A Key Focus Area for Genetic Testing
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Ageing Demographics to Drive Demand for Genetic Testing
    • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 3: World 16-Year Perspective for Prenatal & Newborn by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 6: World 16-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 9: World 16-Year Perspective for Predictive & Presymptomatic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 12: World 16-Year Perspective for Carrier by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 15: World 16-Year Perspective for Pharmacogenomic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 18: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 24: World 16-Year Perspective for Genetic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 27: World 16-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 30: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 31: World Genetic Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • Use of Genomic Data in Clinical Settings to Gather Pace
    • The United States: Leading Market for Genetic Testing Globally
    • Predictive Screening: Another Growth Area
    • Growing Relevance of Personalized Medicine Augurs Well
    • Rising Incidence of Cancer in the US: Driver for Cancer Genetic Testing
    • Newborn Testing Gains Ground
    • Invasive Prenatal Diagnosis Gives Way to Non-Invasive Prenatal Testing
    • Coverage of NIPT in Average Risk Pregnancies Expands Target Market
    • Direct-to-Consumer Testing: A Growing Market
    • Favorable Reimbursement Policies
    • Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing
    • Demographic Changes Offer Growth Opportunities
    • TABLE 14: North American Aging Population by Age Group: 1975-2050
    • Skepticism Limits Widespread Adoption of Genetic Testing
    • Competitive Overview
    • Myriad Eyes Diversification and Expansion for Growth
    • Natera Holds Fort in the NIPT Market
    • Invitae Banks on Low Cost Solutions for Expanding Revenues
    • Regulatory Environment
    • Genetic Information Nondiscrimination Act Boosts Genetic Testing
    • Stricter Regulations for DTC Genetic Testing
    • FDA Attempts to Put a Leash around Unapproved DTC Genetic Tests
    • Select Genetic Test Reimbursement Codes
    • Market Analytics
    • TABLE 35: USA Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030
  • CANADA
    • Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand
    • Regulatory Scenario
    • Market Analytics
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030
  • JAPAN
    • Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • Demographics Drive Market Growth
    • DTC Genetic Testing Regulatory Scenario
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030
  • CHINA
    • Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • Market Overview
    • China Attracts Domestic and Foreign Players
    • Strong Focus on Genomics
    • Genetic Testing to Reveal Real Talent in Children - A New Popular Application
    • China to Take Lead in Rapidly Growing Asian Genomics Market
    • Market Analytics
    • TABLE 53: China Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: China 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030
  • EUROPE
    • Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • European Personalized Medicine Market to Exhibit Robust Growth
    • Aging Population to Drive Demand for Genetic Testing
    • TABLE 28: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15-64, and 65 & Above
    • Legislations/Regulatory Policies in Select European Countries
    • Legislations Governing Genetic Testing in Select European Countries
    • Rising Cancer Incidence Augurs Well for European Genetic Testing Market
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
  • FRANCE
    • Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: France 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: France 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030
  • GERMANY
    • Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • Parliamentary Regulations
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • Increased Support for Personalized Medicine to Drive Genetic Testing
    • SMIP for Pharmacogenomic Testing
    • Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK
    • Principles for DTC Genetic Testing Laid out by HGC
    • TABLE 86: UK Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Genetic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • Healthcare Spending in Asia-Pacific: On the Rise
    • India
    • Australia and New Zealand
    • Market Analytics
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • Predictive Screening: Another Growth Area
    • Market Analytics
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of World 16-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2014, 2025 & 2030
    • TABLE 107: Rest of World Recent Past, Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of World Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Rest of World 16-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2014, 2025 & 2030

IV. COMPETITION